Edaphon is an investment firm. Its connection to the psychedelic field is participation in Octarine Bio's €12.8 million Series A (closed 2026), backing the Danish synthetic-biology company producing pharmaceutical-grade psilocybin via engineered yeast fermentation.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage focus is not listed yet. Psychedelic-market posture: Psychedelic-Adjacent Focus.
Public Portfolio Examples
- Octarine BioSeries A (close) - €12.8 million total Series A (incl. €5 million new capital added Jan 2026) - Jan 22, 2026
Created from documented participation in 1 psychedelic financing round. Profile details beyond documented deals are unverified.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Stage focus is not listed yet.
Investment Focus Areas
Focus areas are not listed yet.
Recorded Investments
Jan 22, 2026
Series A (close) - €12.8 million total Series A (incl. €5 million new capital added Jan 2026)
Danish biotech Octarine Bio closes €12.8 million Series A for sustainable pigments